Skip to main content
Fig. 3 | Stem Cell Research & Therapy

Fig. 3

From: PARP1 inhibitor (PJ34) improves the function of aging-induced endothelial progenitor cells by preserving intracellular NAD+ levels and increasing SIRT1 activity

Fig. 3

Functional alterations in senescent EPCs after PJ34 treatment. a Reactive oxygen species (ROS) production was assessed by DCFH-DA staining after 6 h of treatment. b Intracellular nicotinamide adenine dinucleotide (NAD+) levels were measured after 6 h of treatment. c Cell viability was evaluated by CCK-8 after 24 h of treatment. d, e Senescence was analyzed by senescence-associated beta-galactosidase (SA-β-gal) staining after 24 h of treatment. f–i Tube formation ability was evaluated on Matrigel after 24 h of treatment. j, k Migration ability was analyzed by Transwell assay after 24 h of treatment. *P < 0.05, **P < 0.01, ***P < 0.001, versus the control; #P < 0.05, ##P < 0.01, ###P < 0.001, versus H2O2 treatment

Back to article page